Snappy newsletters. Simple Facebook sharing. Spirited comments. Sweet features are waiting… GET THEM NOW!

Global Patent Pool Scores 4 New AIDS Drugs

It's a major step to benefit poor nations battling disease

By Kevin Spak, Newser Staff

Posted Jul 12, 2011 10:59 AM CDT

(Newser) – Gilead Sciences announced today that it will license four AIDS and hepatitis B drugs to an international patent pool, allowing cheap, generic versions to be produced for sale in low-income countries. The AIDS drugs, which include tenofovir and emtricitabine, represent a major upgrade on the... Read full story »

COMMENTS

Read the comment policy

You need to Log in to Newser to comment. Don't have an account yet? Sign up now!

There are no comments

A snapshot of the day's best news stories.

View Larger Grid

All Today Yesterday Pick a Date

What's Popular Now on Facebook

Japanese Artist Serves Up Own Cooked Genitals

Rape Conviction Cleared, Thanks to Facebook

New York Times (Source Grid »)
Associated Press (Source Grid »)

Health • Great Finds

AIDS • pharmaceutical companies • pharmaceutical • pharmaceutical industry • patent • Gilead Sciences • Medicines Patent Pool

More Newser Stories

Disgraced Doctors Land at Big Pharma

Hundreds of pitchmen found to have blemished records

(NEWSER) - Pharmaceutical companies say they hire highly respected doctors as their white-coat sales force, peddling their drugs to other physicians. But a Pro Publica investigation has discovered that hundreds of these pitchmen have been accused of professional misconduct, been disciplined by state boards, or lacked credentials. Medical board records in the 15 most populous states revealed that more than 250 had been sanctioned, another 40 given FDA warnings for research lapses, and 20 more hit with successful malpractice lawsuits. Some have even lost their licenses. More»

After 20 Years, Scientists Crack HIV Puzzle

Enzyme integrase made visible for first time

(NEWSER) - After 40,000 failed trials and "painstakingly slow progress," scientists have solved a puzzle that stumped AIDS researchers for more than 20 years—and their findings could help develop more effective HIV drugs. The researchers at Harvard and Imperial College London grew a crystal that for the first time made visible the structure of integrase, the enzyme targeted by many newer HIV drugs, Reuters reports. More»

Heparin Supply Chain Shaky in China

Troubles could trace back to vulnerable raw materials

(NEWSER) - With at least four US patients dead and hundreds suffering complications from the blood-thinning drug heparin, the New York Times follows the supply chain back to Chinese slaughterhouses that deal with the pig intestines that provide raw material for the drug. Though companies say the chain is secure, the Times finds it vulnerable to contamination and lack of oversight. More»

FDA Panel Backs First Drug to Block HIV

Truvada, made by Gilead Sciences, is for healthy people at risk

(AP) - A panel of federal health advisers has endorsed the first drug shown to prevent HIV infection in healthy people, clearing the way for a potentially landmark approval in the 30-year-old effort against the virus that causes AIDS. In a series of votes, the FDA advisory panel recommended approval of the daily pill Truvada for healthy people who are at high risk of contracting HIV, including gay and bisexual men, and heterosexual couples with one HIV-infected person. More»

US to Big Pharma: Disclose What You Pay Docs

New rules aim to increase transparency

(NEWSER) - Studies have found that when doctors accept payments from drug companies, it can influence their treatment decisions—so the Obama administration will soon require drug companies to disclose those payments. The New York Times reports that around 25% of doctors receive cash from drug companies for consulting, speaking engagements, and more; in addition, almost two-thirds accept staff lunches or dinners out. The new requirements, part of the new health care law, will ensure that such payments and gifts, even small ones, are disclosed on a website; drug companies will be subject to fines for any omissions. More»

NEWS FROM OUR PARTNERS

What is Newser?

Face it: there's too much news. At Newser, we choose the most thought-provoking and entertaining stories from hundreds of US and international sources and reduce them to a headline, picture, and two paragraphs. And we do it 24/7—you can come back morning, noon, night (and in between) for something new that matters. Read less, know more.

Learn more »

Partnering with: Slate

View Newser on the mobile website

Global Patent Pool Scores 4 New AIDS Drugs

It's a major step to benefit poor nations battling disease

AIDS • pharmaceutical companies • pharmaceutical • pharmaceutical industry • patent • Gilead Sciences • Medicines Patent Pool

MOST POPULAR STORIES

[ By Views ]

[ By Comments ]

More Newser Stories

Disgraced Doctors Land at Big Pharma

Hundreds of pitchmen found to have blemished records

After 20 Years, Scientists Crack HIV Puzzle

Enzyme integrase made visible for first time

Heparin Supply Chain Shaky in China

Troubles could trace back to vulnerable raw materials

FDA Panel Backs First Drug to Block HIV

Truvada, made by Gilead Sciences, is for healthy people at risk

US to Big Pharma: Disclose What You Pay Docs

New rules aim to increase transparency

About Us

Site

Community

Site Maps

Tools

More News

What is Newser?